Mortality from Epilepsy
International Patterns and Changes over TimeMassey E.W.a · Schoenberg B.S.b
a Department of Neurology, Duke University School of Medicine, Durham, N.C., and b Neuroepidemiology Branch, National Institute of Neurological and Communicative Disorders and Stroke, NIH, Bethesda, Md., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Average annual age-adjusted mortality rates for epilepsy from 33 countries for 1967–1973 were calculated and compared to earlier data (when available) from the 1950s. Rates during 1967–1973 range from 0.6 deaths/ 100,000/year (Denmark) to 4.0 deaths/ 100,000/year (Portugal). Countries in Latin America generally have high rates. With few exceptions, epilepsy mortality rates have declined over time. For each country studied, the rates are higher for males. As prevalence surveys are implemented throughout the world, we shall no longer need to rely on mortality statistics to provide some indication of the patterns of epilepsy on an international basis.
© 1985 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.